Effect of Low Dose Glucocorticoid Inhalation on Bronchopulmonary Dysplasia in Premature Infants

Abstract

The aim of the study was to explore the effect of low dose glucocorticoid on bronchopulmonary dysplasia in premature infants, to provide new ideas for clinical prevention and cure of bronchopulmonary dysplasia in premature infants. The 144 cases of premature infants were divided into 72 each: control group and experimental group. Control group received routine clinical prevention and cure, while experimental group was received low dose glucocorticoid on the basis of control group. The serum interleukin-10 (IL-10) , interleukin-8 (IL-8), and transforming growth factor-1 (TGF-β1) before and after treatment were compared between two groups. The incidence and severity of bronchopulmonary dysplasia was compared between two groups. The mechanical ventilation time, oxygen inhalation time and hospitalization time in two groups were recorded, and the body mass, head circumference and body length at 30 days after birth were assessed in both groups. After treatment, the serum IL-10 level in experimental group was increased and IL-8, TGF-β1 levels were decreased compared with control group (p <0.05). The incidence rate of bronchopulmonary dysplasia in experimental group was 13.89% and the disease severity in experimental group was significantly reduced (p<0.05). Both groups exhibited no notable adverse reactions (p>0.05). Low-dose glucocorticoids have a significant preventive and therapeutic effect on bronchopulmonary dysplasia in preterm infants, and have a high safety, showing high clinical application value for bronchopulmonary dysplasia in preterm infants.

Keywords

glucocorticoid - bronchopulmonary dysplasia - premature infants - low dose - prevention and treatment effect

Publication History

Received: 08 July 2024

Accepted after revision: 05 September 2024

Article published online:
30 September 2024

• References

• 1 Jensen EA, Dysart K, Gantz MG. et al. The diagnosis of bronchopulmonary dysplasia in very preterm infants. An evidence-based approach. Am J Respir Crit Care Med 2019; 200: 751-759
• 2 Salimi U, Dummula K, Tucker MH. et al. Postnatal sepsis and bronchopulmonary dysplasia in premature infants: mechanistic insights into “New BPD”. Am J Respir Cell Mol Biol 2022; 66: 137-145
• 3 Htun ZT, Schulz EV, Desai RK. et al. Postnatal steroid management in preterm infants with evolving bronchopulmonary dysplasia. J Perinatol 2021; 41: 1783-1796
• 4 Doyle LW. Postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Neonatology 2021; 118: 244-251
• 5 Lv Y, Li Y, Wang J. et al. MiR-382-5p suppresses M1 macrophage polarization and inflammatory response in response to bronchopulmonary dysplasia through targeting CDK8: Involving inhibition of STAT1 pathway. Genes Cells 2021; 26: 772-781
• 6 Ramaswamy VV, Bandyopadhyay T, Nanda D. et al. Assessment of postnatal corticosteroids for the prevention of bronchopulmonary dysplasia in preterm neonates: a systematic review and network meta-analysis. JAMA Pediatr 2021; 175: e206826
• 7 Moraes LHA, Coelho RMD, Neves Dos Santos Beozzo GP. et al. Use of budesonide associated with a pulmonary surfactant to prevent bronchopulmonary dysplasia in premature newborns – a systematic review. J Pediatr (Rio J) 2023; 99: 105-111
• 8 Du FL, Dong WB, Zhang C. et al. Budesonide and poractant alfa prevent bronchopulmonary dysplasia via triggering SIRT1 signaling pathway. Eur Rev Med Pharmacol Sci 2019; 23: 11032-11042
• 9 Gharehbaghi MM, Mhallei M, Ganji S. et al. The efficacy of intratracheal administration of surfactant and budesonide combination in the prevention of bronchopulmonary dysplasia. J Res Med Sci 2021; 26: 31
• 10 Zhang C, Hediger ML, Albert PS. et al. Association of maternal obesity with longitudinal ultrasonographic measures of fetal growth: findings from the NICHD fetal growth studies-singletons. JAMA Pediatr 2018; 172: 24-31
• 11 Starr MC, Wilson AC. Systemic hypertension in infants with bronchopulmonary dysplasia. Curr Hypertens Rep 2022; 24: 193-203
• 12 Shukla VV, Ambalavanan N. Recent advances in bronchopulmonary dysplasia. Indian J Pediatr 2021; 88: 690-695
• 13 Homan TD, Nayak RP. Short- and long-term complications of bronchopulmonary dysplasia. Respir Care 2021; 66: 1618-1629
• 14 Hocq C, Vanhoutte L, Guilloteau A. et al. Early diagnosis and targeted approaches to pulmonary vascular disease in bronchopulmonary dysplasia. Pediatr Res 2022; 91: 804-815
• 15 Muehlbacher T, Bassler D, Bryant MB. Evidence for the management of bronchopulmonary dysplasia in very preterm infants. Children (Basel) 2021; 8: 298-328
• 16 Holzfurtner L, Shahzad T, Dong Y. et al. When inflammation meets lung development-an update on the pathogenesis of bronchopulmonary dysplasia. Mol Cell Pediatr 2022; 9: 7-18
• 17 Watterberg KL, Walsh MC, Li L, Chawla S. et al. Hydrocortisone to improve survival without bronchopulmonary dysplasia. N Engl J Med 2022; 386: 1121-1131
• 18 Rüegger CM, Bassler D. Alternatives to systemic postnatal corticosteroids: Inhaled, nebulized and intratracheal. Semin Fetal Neonatal Med 2019; 24: 207-212
• 19 Sahni M, Yeboah B, Das P. et al. Novel biomarkers of bronchopulmonary dysplasia and bronchopulmonary dysplasia-associated pulmonary hypertension. J Perinatol 2020; 40: 1634-1643
• 20 Ruschkowski BA, Esmaeil Y, Daniel K. et al. Thrombospondin-1 plays a major pathogenic role in experimental and human bronchopulmonary dysplasia. Am J Respir Crit Care Med 2022; 205: 685-699
• 21 Yao Y, Zhang G, Wang F. et al. Efficacy of budesonide in the prevention and treatment of bronchopulmonary dysplasia in premature infants and its effect on pulmonary function. Am J Transl Res 2021; 13: 4949-4958
• 22 Liu MM, Ji L, Dong MY. et al. Efficacy and safety of intratracheal administration of budesonide combined with pulmonary surfactant in preventing bronchopulmonary dysplasia: a prospective randomized controlled trial. Zhongguo Dang Dai Er Ke Za Zhi 2022; 24: 78-84